Table 1 Baseline patient characteristics and demographics of full analysis set
From: A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Placebo (N = 83) | 600 mg (N = 76) | 900 mg (N = 83) | p value | |
|---|---|---|---|---|
Gender | 0.519a | |||
Male | 31 (37.4%) | 35 (46.1%) | 33 (39.8%) | |
Female | 52 (62.7%) | 41 (54.0%) | 50 (60.2%) | |
Age (years) | 70.3 (8.1) | 70.3 (8.4) | 70.4 (8.5) | 1.00b |
Ethnicity | 0.76a | |||
Han Chinese | 83 (100.0%) | 75 (98.7%) | 82 (98.8%) | |
Others | 0 (0.0%) | 1 (1.3%) | 1 (1.2%) | |
Height (cm) | 161.7 (8.8) | 163.1 (7.2) | 162.5 (7.6) | 0.52b |
Weight (kg) | 58 (10.4) | 60 (9.9) | 59 (10.0) | 0.20b |
Education | 0.80a | |||
6 years | 31 (37.4%) | 22 (29.0%) | 27 (32.5%) | |
More than 6 years | 52 (62.7%) | 54 (71.1%) | 56 (67.5%) | |
Breathing (times/minute) | 18 (2.0) | 18 (2.1) | 18 (2.1) | 0.54b |
Diastolic blood pressure (mmHg) | 126 (12.0) | 124 (11.8) | 126 (11.2) | 0.65b |
Systolic blood pressure (mmHg) | 76 (7.0) | 78 (7.4) | 76 (8.1) | 0.24b |
Pulse (times/minute) | 74 (10.0) | 75 (8.9) | 74 (8.7) | 0.85b |
HIS | 1.3 (0.9) | 1.5 (0.9) | 1.3 (0.9) | 0.88b |
HAMD | 3.3 (2.7) | 3.4 (2.8) | 3.1 (2.7) | 0.28b |
MMSE | 17.5 (4.2) | 18.3 (4.8) | 18.1 (4.4) | 0.20b |